Personal profile
Research interests
Lab Overview
The High Throughput Screening Facility (HTSF) provides a resource for investigators to incorporate high throughput approaches and technology platforms for the advancement of translational research programs. In my role as Manager of the HTSF, my aim is to enable each investigator to utilize the reagents and technologies in the facility to further the overall research program in their individual laboratory. Towards this end, I provide consultation on screening projects and assist in the development and performance of small molecule and RNAi screens. In addition, the HTSF provides unique instrumentation on the FCCC campus that can be utilized in both HTS and non-screening projects. For investigators seeking more limited use of instrumentation, I offer advice and training to their laboratory personnel to allow them to select and apply optimal applications of the HTS technology for their experiments of interest. In addition, I coordinate between facilities for HTSF projects (such as the Biosample Repository or the Biostatistics Facility) to assist researchers to move their science forward as efficiently as possible. In another role, I provide support of clinical investigators, supporting the development and implementation of research correlates for clinical studies.
Research interests
- The HTSF offers expertise and specialized technology platforms providing support for translational projects within laboratory and clinic-based research programs
- Provide education, expertise and instrumentation for researchers to employ high throughput approaches
- Assist investigators to execute high throughput screens using small molecule and RNAi libraries to understand and target cellular pathways to identify potential cancer therapeutics
- Provide support and materials for grant and publication submission
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
Inhibiting acute, axonal DLK palmitoylation is neuroprotective and avoids deleterious effects of cell-wide DLK inhibition
Zhang, X., Jeong, H., Niu, J., Holland, S. M., Rotanz, B. N., Gordon, J., Einarson, M. B., Childers, W. E. & Thomas, G. M., Apr 3 2025, In: Nature Communications. 16, 1, p. 3031 19 p., 3031.Research output: Contribution to journal › Article › peer-review
3 Scopus citations -
Novel inhibitors of acute, axonal DLK palmitoylation are neuroprotective and avoid the deleterious side effects of cell-wide DLK inhibition
Zhang, X., Jeong, H., Niu, J., Holland, S. M., Rotanz, B. N., Gordon, J., Einarson, M. B., Childers, W. E. & Thomas, G. M., Apr 24 2024, In: bioRxiv : the preprint server for biology.Research output: Contribution to journal › Article › peer-review
-
A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors
Zibelman, M., MacFarlane, A. W., Costello, K., McGowan, T., O’Neill, J., Kokate, R., Borghaei, H., Denlinger, C. S., Dotan, E., Geynisman, D. M., Jain, A., Martin, L., Obeid, E., Devarajan, K., Ruth, K., Alpaugh, R. K., Dulaimi, E. A. S., Cukierman, E., Einarson, M. & Campbell, K. S. & 1 others, , Jun 27 2023, In: Nature Communications. 14, 1, p. 4513 4513.Research output: Contribution to journal › Article › peer-review
Open Access25 Scopus citations -
Trogocytosis of cancer-associated fibroblasts promotes pancreatic cancer growth and immune suppression via phospholipid scramblase anoctamin 6 (ANO6)
Ogier, C., Solomon, A. M. C., Lu, Z., Recoules, L., Klochkova, A., Gabitova-Cornell, L., Bayarmagnai, B., Restifo, D., Surumbayeva, A., Vendramini-Costa, D. B., Deneka, A. Y., Francescone, R., Lilly, A. C., Sipman, A., Gardiner, J. C., Luong, T., Franco-Barraza, J., Ibeme, N., Cai, K. Q. & Einarson, M. B. & 13 others, , 2023, (bioRxiv : the preprint server for biology).Research output: Working paper › Preprint
-
Correction to: Thymine DNA glycosylase as a novel target for melanoma
Mancuso, P., Tricarico, R., Bhattacharjee, V., Cosentino, L., Kadariya, Y., Jelinek, J., Nicolas, E., Einarson, M., Beeharry, N., Devarajan, K., Katz, R. A., Dorjsuren, D. G., Sun, H., Simeonov, A., Giordano, A., Testa, J. R., Davidson, G., Davidson, I., Larue, L. & Sobol, R. W. & 2 others, , May 2022, In: Oncogene. 41, 23, p. 3300-3301 2 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations
Press/Media
-
HMN 2025: How A brand new focused strategy may defend neurons in opposition to degeneration
04/4/25
1 item of Media coverage
Press/Media
-
Neurodegenerative Disease Treatment Strategy Sparked by Novel DLK Inhibitor
04/4/25
1 item of Media coverage
Press/Media
-
Researchers at the Lewis Katz School of Medicine at Temple University identify new targeted approach to protect neurons against degeneration
04/3/25
2 items of Media coverage
Press/Media
-
Fox Chase Cancer Center and the Lewis Katz School of Medicine at Temple University Present Research at the American Association of Cancer Research Annual Meeting 2024
Cai, K. Q., Devarajan, K., Chernoff, J., Flieder, D. B., Nejati, R. M., Einarson, M., Abbosh, P., Edelman, M., Golemis, E. A., Meyer, J. E., Yang, Y., Mitchell, K. A., Campbell, K. S., Chhabra, Y., Galloway, T. J., Zhou, Y., Balachandran, S., Fane, M., Clapper, M., Testa, J. R., Arora, S., Baldwin, D. & Desai, P. A.
04/5/24
1 item of Media coverage
Press/Media
-
New Solid Cancer Research Has Been Reported by Researchers at Fox Chase Cancer Center (A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors)
Devarajan, K., Borghaei, H., Plimack, E. R., Dotan, E., Einarson, M. B., Jain, A., Zibelman, M. R., Campbell, K. S., Cukierman, E. & Geynisman, D.
08/11/23
1 item of Media coverage
Press/Media